Ischemic Heart Disease Treatment
Dr. Ahmed Mohammed Ahmed
Applied Clinical Anatomy, Al- Yarmouk Teaching Hospital, Iraq
Abdullah Abdulkhaliq Qazzaz
High Diploma of Emergency Medicine, Al- Yarmouk Teaching Hospital, Iraq
Dr. Hydair Sachet Khalaf
M. Sc Pharmacology Therapeutics, Al- Yarmouk Teaching Hospital, Iraq
39-41
Vol: 12, Issue: 1, 2022
Receiving Date:
2022-01-10
Acceptance Date:
2022-02-24
Publication Date:
2022-03-27
Download PDF
http://doi.org/10.37648/ijrst.v12i01.005
Abstract
Ischemic heart disease IHD is a rapidly increasing common cause of death in the world. This disease is the insufficient status of oxygen within the cardiac muscles due to an imbalance between oxygen supply and demand, and a cardiac disease that occurs as a result of coronary artery stenosis. Ischemic heart disease diseases are the leading cause of death in both developed and developing countries ,among these IHD is the most prevalent manifestation and is associated with high mortality and morbidity. The clinical presentation of IHD include silent ischaemia, stable angina, unstable angina, myocardial infarction, heart failure and sudden death.
Keywords:
Ischemic; IHD; sudden death
References
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-477.
- Braunwald E. Coronary-artery surgery at the crossroads. N Engl J Med 1977;297:661-663.
- Stone GW, Hochman JS, Williams DO, et al. Medical therapy with versus without revascularization in stable patients with moderate and severe ischemia: the case for community equipoise. J Am Coll Cardiol 2016;67:81-99.
- Chacko L, Howard JP, Rajkumar C, et al. Effects of percutaneous coronary intervention on death and myocardial infarction stratified by stable and unstable coronary artery disease: a meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2020;13(2):e006363-e006363.
- Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2020;382:1395-1407.
- Bangalore S, Maron DJ, O’Brien SM, et al. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. DOI: 10.1056/NEJMoa1915925.
- Spertus JA, Jones PG, Maron DJ, et al. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med 2020;382:1408-1419.
- Spertus JA, Jones PG, Maron DJ, et al. Health status after invasive or conservative care in coronary and advanced kidney disease. N Engl J Med. DOI: 10.1056/NEJMoa1916374.
- Hochman JS, Reynolds HR, Bangalore S, et al. Baseline characteristics and risk profiles of participants in the ISCHEMIA randomized clinical trial. JAMA Cardiol 2019;4:273-286.
- ISCHEMIA Trial Research Group. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: rationale and design. Am Heart J 2018;201:124-135.
- Antman EM, Loscalzo J. Precision medicine in cardiology. Nat Rev Cardiol 2016;13:591-602.
- Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339-352.
Back
